Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Kallikrein 6 protease advances colon tumorigenesis via induction of the high mobility group A2 protein.

Chen H, Sells E, Pandey R, Abril ER, Hsu CH, Krouse RS, Nagle RB, Pampalakis G, Sotiropoulou G, Ignatenko NA.

Oncotarget. 2019 Oct 22;10(58):6062-6078. doi: 10.18632/oncotarget.27153. eCollection 2019 Oct 22.

2.

Synthesis and Structure-Activity Relationships of N-(4-Benzamidino)-Oxazolidinones: Potent and Selective Inhibitors of Kallikrein-Related Peptidase 6.

De Vita E, Smits N, van den Hurk H, Beck EM, Hewitt J, Baillie G, Russell E, Pannifer A, Hamon V, Morrison A, McElroy SP, Jones P, Ignatenko NA, Gunkel N, Miller AK.

ChemMedChem. 2019 Nov 1. doi: 10.1002/cmdc.201900536. [Epub ahead of print]

PMID:
31675166
3.

Somatic evolution and global expansion of an ancient transmissible cancer lineage.

Baez-Ortega A, Gori K, Strakova A, Allen JL, Allum KM, Bansse-Issa L, Bhutia TN, Bisson JL, Briceño C, Castillo Domracheva A, Corrigan AM, Cran HR, Crawford JT, Davis E, de Castro KF, B de Nardi A, de Vos AP, Delgadillo Keenan L, Donelan EM, Espinoza Huerta AR, Faramade IA, Fazil M, Fotopoulou E, Fruean SN, Gallardo-Arrieta F, Glebova O, Gouletsou PG, Häfelin Manrique RF, Henriques JJGP, Horta RS, Ignatenko N, Kane Y, King C, Koenig D, Krupa A, Kruzeniski SJ, Kwon YM, Lanza-Perea M, Lazyan M, Lopez Quintana AM, Losfelt T, Marino G, Martínez Castañeda S, Martínez-López MF, Meyer M, Migneco EJ, Nakanwagi B, Neal KB, Neunzig W, Ní Leathlobhair M, Nixon SJ, Ortega-Pacheco A, Pedraza-Ordoñez F, Peleteiro MC, Polak K, Pye RJ, Reece JF, Rojas Gutierrez J, Sadia H, Schmeling SK, Shamanova O, Sherlock AG, Stammnitz M, Steenland-Smit AE, Svitich A, Tapia Martínez LJ, Thoya Ngoka I, Torres CG, Tudor EM, van der Wel MG, Viţălaru BA, Vural SA, Walkinton O, Wang J, Wehrle-Martinez AS, Widdowson SAE, Stratton MR, Alexandrov LB, Martincorena I, Murchison EP.

Science. 2019 Aug 2;365(6452). pii: eaau9923. doi: 10.1126/science.aau9923.

PMID:
31371581
4.

Synthesis and antimycobacterial activity of imidazo[1,2-b][1,2,4,5]tetrazines.

Maslov DA, Korotina AV, Shur KV, Vatlin AA, Bekker OB, Tolshchina SG, Ishmetova RI, Ignatenko NK, Rusinov GL, Charushin VN, Danilenko VN.

Eur J Med Chem. 2019 Sep 15;178:39-47. doi: 10.1016/j.ejmech.2019.05.081. Epub 2019 May 31.

PMID:
31176094
5.

Does Mutated K-RAS Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention?

Rice PFS, Ehrichs KG, Jones MS, Chen H, Hsu CH, Abril ER, Nagle RB, Besselsen DG, Barton JK, Ignatenko NA.

Cancer Prev Res (Phila). 2018 Jan;11(1):16-26. doi: 10.1158/1940-6207.CAPR-17-0230. Epub 2017 Nov 8.

6.

Detection of Enzyme Activity and Inhibition during Studies in Solution, In Vitro and In Vivo with CatalyCEST MRI.

Sinharay S, Randtke EA, Howison CM, Ignatenko NA, Pagel MD.

Mol Imaging Biol. 2018 Apr;20(2):240-248. doi: 10.1007/s11307-017-1092-8.

7.

Specific microRNA-mRNA Regulatory Network of Colon Cancer Invasion Mediated by Tissue Kallikrein-Related Peptidase 6.

Sells E, Pandey R, Chen H, Skovan BA, Cui H, Ignatenko NA.

Neoplasia. 2017 May;19(5):396-411. doi: 10.1016/j.neo.2017.02.003. Epub 2017 Apr 18.

8.

Mitochondrial genetic diversity, selection and recombination in a canine transmissible cancer.

Strakova A, Ní Leathlobhair M, Wang GD, Yin TT, Airikkala-Otter I, Allen JL, Allum KM, Bansse-Issa L, Bisson JL, Castillo Domracheva A, de Castro KF, Corrigan AM, Cran HR, Crawford JT, Cutter SM, Delgadillo Keenan L, Donelan EM, Faramade IA, Flores Reynoso E, Fotopoulou E, Fruean SN, Gallardo-Arrieta F, Glebova O, Häfelin Manrique RF, Henriques JJ, Ignatenko N, Koenig D, Lanza-Perea M, Lobetti R, Lopez Quintana AM, Losfelt T, Marino G, Martincorena I, Martínez Castañeda S, Martínez-López MF, Meyer M, Nakanwagi B, De Nardi AB, Neunzig W, Nixon SJ, Onsare MM, Ortega-Pacheco A, Peleteiro MC, Pye RJ, Reece JF, Rojas Gutierrez J, Sadia H, Schmeling SK, Shamanova O, Ssuna RK, Steenland-Smit AE, Svitich A, Thoya Ngoka I, Vițălaru BA, de Vos AP, de Vos JP, Walkinton O, Wedge DC, Wehrle-Martinez AS, van der Wel MG, Widdowson SA, Murchison EP.

Elife. 2016 May 17;5. pii: e14552. doi: 10.7554/eLife.14552.

9.

ANIMAL MODELS OF CANCER BIOLOGY.

Yee NS, Ignatenko N, Finnberg N, Lee N, Stairs D.

Cancer Growth Metastasis. 2015 Dec 10;8(Suppl 1):115-8. doi: 10.4137/CGM.S37907. eCollection 2015. No abstract available.

10.

Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways.

Padavano J, Henkhaus RS, Chen H, Skovan BA, Cui H, Ignatenko NA.

Cancer Growth Metastasis. 2015 Oct 19;8(Suppl 1):95-113. doi: 10.4137/CGM.S29407. eCollection 2015.

11.

Time-serial Assessment of Drug Combination Interventions in a Mouse Model of Colorectal Carcinogenesis Using Optical Coherence Tomography.

LeGendre-McGhee S, Rice PS, Wall RA, Sprute KJ, Bommireddy R, Luttman AM, Nagle RB, Abril ER, Farrell K, Hsu CH, Roe DJ, Gerner EW, Ignatenko NA, Barton JK.

Cancer Growth Metastasis. 2015 Sep 7;8(Suppl 1):63-80. doi: 10.4137/CGM.S21216. eCollection 2015.

12.

Get the fat out!

Ignatenko NA, Gerner EW.

Cancer Prev Res (Phila). 2013 Mar;6(3):161-4. doi: 10.1158/1940-6207.CAPR-13-0025.

13.

Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis.

Basu Roy UK, Henkhaus RS, Loupakis F, Cremolini C, Gerner EW, Ignatenko NA.

Int J Cancer. 2013 Jul;133(1):43-57. doi: 10.1002/ijc.28001. Epub 2013 Feb 12. Erratum in: Int J Cancer. 2015 Oct 15;137(8):E18.

14.

Polyamines in cancer.

Paz EA, Garcia-Huidobro J, Ignatenko NA.

Adv Clin Chem. 2011;54:45-70. Review.

PMID:
21874756
15.

Defining the role of polyamines in colon carcinogenesis using mouse models.

Ignatenko NA, Gerner EW, Besselsen DG.

J Carcinog. 2011;10:10. doi: 10.4103/1477-3163.79673. Epub 2011 Apr 16.

16.

Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival.

Zell JA, Ziogas A, Ignatenko N, Honda J, Qu N, Bobbs AS, Neuhausen SL, Gerner EW, Anton-Culver H.

Clin Cancer Res. 2009 Oct 1;15(19):6208-16. doi: 10.1158/1078-0432.CCR-09-0592. Epub 2009 Sep 29.

17.

Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047.

Ignatenko NA, Yerushalmi HF, Pandey R, Kachel KL, Stringer DE, Marton LJ, Gerner EW.

Cancer Genomics Proteomics. 2009 May-Jun;6(3):161-75.

18.

Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.

Ignatenko NA, Besselsen DG, Stringer DE, Blohm-Mangone KA, Cui H, Gerner EW.

Nutr Cancer. 2008;60 Suppl 1:30-5. doi: 10.1080/01635580802401317.

PMID:
19003578
19.

Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells.

Henkhaus RS, Gerner EW, Ignatenko NA.

Biol Chem. 2008 Jun;389(6):757-64. doi: 10.1515/BC.2008.087.

20.

Wild-type APC regulates caveolin-1 expression in human colon adenocarcinoma cell lines via FOXO1a and C-myc.

Roy UK, Henkhaus RS, Ignatenko NA, Mora J, Fultz KE, Gerner EW.

Mol Carcinog. 2008 Dec;47(12):947-55. doi: 10.1002/mc.20451.

21.

HuRrying colon cancer progression.

Ignatenko NA, Gerner EW.

Cancer Biol Ther. 2008 Mar;7(3):428-9. Epub 2007 Feb 2. No abstract available.

22.

Caveolin-1-mediated expression and secretion of kallikrein 6 in colon cancer cells.

Henkhaus RS, Roy UK, Cavallo-Medved D, Sloane BF, Gerner EW, Ignatenko NA.

Neoplasia. 2008 Feb;10(2):140-8.

23.

Serial endoscopy in azoxymethane treated mice using ultra-high resolution optical coherence tomography.

Hariri LP, Qiu Z, Tumlinson AR, Besselsen DG, Gerner EW, Ignatenko NA, Povazay B, Hermann B, Sattmann H, McNally J, Unterhuber A, Drexler W, Barton JK.

Cancer Biol Ther. 2007 Nov;6(11):1753-62. Epub 2007 Aug 12.

PMID:
17986850
24.

Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis.

Ignatenko NA, Besselsen DG, Roy UK, Stringer DE, Blohm-Mangone KA, Padilla-Torres JL, Guillen-R JM, Gerner EW.

Nutr Cancer. 2006;56(2):172-81.

25.

Deoxycholate-induced colitis is markedly attenuated in Nos2 knockout mice in association with modulation of gene expression profiles.

Bernstein H, Holubec H, Bernstein C, Ignatenko NA, Gerner E, Dvorak K, Besselsen D, Blohm-Mangone KA, Padilla-Torres J, Dvorakova B, Garewal H, Payne CM.

Dig Dis Sci. 2007 Mar;52(3):628-42.

PMID:
17253130
26.

Pharmacogenomics of the polyamine analog 3,8,13,18-tetraaza-10,11-[(E)-1,2-cyclopropyl]eicosane tetrahydrochloride, CGC-11093, in the colon adenocarcinoma cell line HCT1161.

Ignatenko NA, Yerushalmi HF, Watts GS, Futscher BW, Stringer DE, Marton LJ, Gerner EW.

Technol Cancer Res Treat. 2006 Dec;5(6):553-64.

PMID:
17121431
27.

Role of c-Myc in intestinal tumorigenesis of the ApcMin/+ mouse.

Ignatenko NA, Holubec H, Besselsen DG, Blohm-Mangone KA, Padilla-Torres JL, Nagle RB, de Alboránç IM, Guillen-R JM, Gerner EW.

Cancer Biol Ther. 2006 Dec;5(12):1658-64. Epub 2006 Dec 7.

PMID:
17106247
28.

Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival.

Zell JA, Ignatenko NA, Yerushalmi HF, Ziogas A, Besselsen DG, Gerner EW, Anton-Culver H.

Int J Cancer. 2007 Feb 1;120(3):459-68.

29.

Role of polyamines in arginine-dependent colon carcinogenesis in Apc(Min) (/+) mice.

Yerushalmi HF, Besselsen DG, Ignatenko NA, Blohm-Mangone KA, Padilla-Torres JL, Stringer DE, Guillen JM, Holubec H, Payne CM, Gerner EW.

Mol Carcinog. 2006 Oct;45(10):764-73.

PMID:
16705737
30.

Unique dietary-related mouse model of colitis.

Bernstein H, Holubec H, Bernstein C, Ignatenko N, Gerner E, Dvorak K, Besselsen D, Ramsey L, Dall'Agnol M, Blohm-Mangone KA, Padilla-Torres J, Cui H, Garewal H, Payne CM.

Inflamm Bowel Dis. 2006 Apr;12(4):278-93.

PMID:
16633050
31.

A comprehensive strategy to combat colon cancer targeting the adenomatous polyposis coli tumor suppressor gene.

Gerner EW, Ignatenko NA, Lance P, Hurley LH.

Ann N Y Acad Sci. 2005 Nov;1059:97-105. Review.

PMID:
16382048
32.

The role of NO synthases in arginine-dependent small intestinal and colonic carcinogenesis.

Yerushalmi HF, Besselsen DG, Ignatenko NA, Blohm-Mangone KA, Padilla-Torres JL, Stringer DE, Cui H, Holubec H, Payne CM, Gerner EW.

Mol Carcinog. 2006 Feb;45(2):93-105.

PMID:
16329147
33.

Role of polyamines in the function of nuclear transcription factor NF-kappaB in breast cancer cells.

Zaletok S, Alexandrova N, Berdynskykh N, Ignatenko N, Gogol S, Orlovsky O, Tregubova N, Gerner E, Chekhun V.

Exp Oncol. 2004 Sep;26(3):221-5.

PMID:
15494691
34.

The chemopreventive agent alpha-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells.

Ignatenko NA, Zhang H, Watts GS, Skovan BA, Stringer DE, Gerner EW.

Mol Carcinog. 2004 Apr;39(4):221-33.

PMID:
15057874
35.

Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells.

Ignatenko NA, Babbar N, Mehta D, Casero RA Jr, Gerner EW.

Mol Carcinog. 2004 Feb;39(2):91-102.

PMID:
14750214
36.

Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer.

Babbar N, Ignatenko NA, Casero RA Jr, Gerner EW.

J Biol Chem. 2003 Nov 28;278(48):47762-75. Epub 2003 Sep 23.

37.

Preclinical models for chemoprevention of colon cancer.

Gerner EW, Ignatenko NA, Besselsen DG.

Recent Results Cancer Res. 2003;163:58-71; discussion 264-6. Review.

PMID:
12903843
38.

Regulation of the HIV1 long terminal repeat by mutant heat shock factor.

Ignatenko NA, Gerner EW.

Exp Cell Res. 2003 Aug 1;288(1):1-8.

PMID:
12878154
39.

Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine.

Qu N, Ignatenko NA, Yamauchi P, Stringer DE, Levenson C, Shannon P, Perrin S, Gerner EW.

Biochem J. 2003 Oct 15;375(Pt 2):465-70.

40.

Comparison of the effectiveness of WHO short-course chemotherapy and standard Russian antituberculous regimens in Tomsk, western Siberia.

Mawer C, Ignatenko N, Wares D, Strelis A, Golubchikova V, Yanova G, Lyagoshina T, Sharaburova O, Banatvala N.

Lancet. 2001 Aug 11;358(9280):445-9.

PMID:
11513907
41.

Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells.

Taylor MT, Lawson KR, Ignatenko NA, Marek SE, Stringer DE, Skovan BA, Gerner EW.

Cancer Res. 2000 Dec 1;60(23):6607-10.

42.

Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine.

Lawson KR, Ignatenko NA, Piazza GA, Cui H, Gerner EW.

Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1155-62.

43.

[The efficacy of reflexotherapy methods in the rehabilitation of servicemen with the sequelae of closed craniocerebral trauma].

Azarova EK, Shakula AV, Kozhekin IG, Liamin MV, Ignatenko NE.

Voen Med Zh. 2000 Feb;321(2):48-51. Russian. No abstract available.

PMID:
10870448
44.

APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse.

Erdman SH, Ignatenko NA, Powell MB, Blohm-Mangone KA, Holubec H, Guillén-Rodriguez JM, Gerner EW.

Carcinogenesis. 1999 Sep;20(9):1709-13.

PMID:
10469614
45.

[The first results of the international project "Tuberculosis in the Tomsk region"].

Strelis AK, Peremitin GG, Shaburova OE, Ianova GV, Golubchikova VT, Chukova NV, Bess K, Moer K, Ignatenko N, Liagoshina T.

Probl Tuberk. 1997;(1):10-2. Review. Russian. No abstract available.

PMID:
9162909
46.

Expression of the human spermidine/spermine N1-acetyltransferase in spermidine acetylation-deficient Escherichia coli.

Ignatenko NA, Fish JL, Shassetz LR, Woolridge DP, Gerner EW.

Biochem J. 1996 Oct 15;319 ( Pt 2):435-40.

47.

Tuberculosis in Siberia: 2. Diagnosis, chemoprophylaxis and treatment.

Drobniewski F, Tayler E, Ignatenko N, Paul J, Connolly M, Nye P, Lyagoshina T, Besse C.

Tuber Lung Dis. 1996 Aug;77(4):297-301.

PMID:
8796243
48.

Tuberculosis in Siberia: 1. An epidemiological and microbiological assessment.

Drobniewski F, Tayler E, Ignatenko N, Paul J, Connolly M, Nye P, Lyagoshina T, Besse C.

Tuber Lung Dis. 1996 Jun;77(3):199-206.

PMID:
8758101
49.
50.

[International concept of antituberculous care organization for the Tomsk region's population].

Strelis AK, Sharaburova OE, Ianova GV, Golubchikova VT, Polivakho VV, Petrova EV, Chukova NV, Bess K, Moer K, Ignatenko N, Liagoshina T.

Probl Tuberk. 1996;(5):5-8. Russian.

PMID:
8984495

Supplemental Content

Loading ...
Support Center